ILM1 Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers all activities in the international environment from the procurement of Active Pharmaceutical Ingredients, the sterile and non-sterile drugs and the supply of public and hospital pharmacies through homecare service. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. Medios AG was founded in 2015 and is headquartered in Berlin, Germany.…
Industry Peers
Medical DistributionKey Statistics
About Medios (ETR: ILM1)
›
Medios (ETR: ILM1) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Distribution industry, part of the Healthcare sector, and reports about 960 employees.
The shares were at 10.46 EUR on 20 November 2026, down 25.1% over 52 weeks. Its 52-week range is 9.980 EUR to 17.44 EUR: the price is 40.0% below the high and 4.8% above the low.
At a market capitalisation of 266.79M EUR, it trades at 29.9 times trailing earnings and 6.2 times forward earnings. The median trailing P/E of its 17 largest Medical Distribution peers is 19.9, a premium of 50% for ILM1.
Medios reports return on equity of 3.0%, an operating margin of 1.7% and revenue up 3.7% year over year.
Its debt exceeds its cash by 104.06M EUR, a debt-to-equity ratio of 0.37. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 19.63 EUR is 87.6% above the current price. The next earnings report is expected on 25 March 2027.